Jorge A. Garcia, MD, FA, describes the case of a 72-year-old man with metastatic castration-resistant prostate cancer.
Targeted Oncology
Articles by Targeted Oncology
Patrick G. Pilié, MD, presents data from the phase 3 PROSPER trial of enzalutamide, and Ganesh V Raj, MD, PhD, presents data from the phase 3 ARAMIS trial of darolutamide for nonmetastatic castration-resistant prostate cancer (nmCRPC).
Ganesh V Raj, MD, PhD, presents data from the phase 3 SPARTAN trial of apalutamide for nonmetastatic castration-resistant prostate cancer (nmCRPC).
Experts in genitourinary oncology discuss how they choose therapy for patients with long PSA doubling times in nonmetastatic castration-resistant prostate cancer (nmCRPC).
Experts in genitourinary oncology share how they decide between the 3 antiandrogen therapies for nonmetastatic castration-resistant prostate cancer: apalutamide, enzalutamide, and darolutamide.
Experts in genitourinary oncology share their methods and patient specific factors that aid in selecting therapy for nonmetastatic castration-resistant prostate cancer.
Ganesh V Raj, MD, PhD, and Mary-Ellen Taplin, MD, review the role of next-generation sequencing in nonmetastatic castration-resistant prostate cancer, and who qualifies based on NCCN guidelines.
Mary-Ellen Taplin, MD, reviews the criteria used to initiate androgen deprivation therapy in the setting of rising PSA syndrome for patients with nonmetastatic castration-resistant prostate cancer.
Ganesh V Raj, MD, PhD, shares his approach to radiation therapy in patients with nonmetastatic castration-resistant prostate cancer.
Experts in genitourinary oncology share their use of novel imaging in practice for nonmetastatic castration-resistant prostate cancer.
Jorge A. Garcia, MD, FACP, describes the case of a 57-year-old African American man with nonmetastatic castration-resistant prostate cancer, and Ganesh V Raj, MD, PhD, reviews how the MRI/TRUS fusion biopsy is becoming a mainstay in diagnosis.
Experts in genitourinary cancer review 2 clinical cases and address major changes in the management of patients with castration-resistant prostate cancer.
Looking forward to further combinations and approaches for frontline and second-line therapy in advanced, unresectable hepatocellular carcinoma.
Efficacy, safety, and quality of life data from IMbrave150 have changed the standard of care for unresectable hepatocellular carcinoma.
Recent updates from the IMbrave150 study, which led to the FDA approval of frontline atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma [HCC].
Richard S. Finn, MD, provides an overview of the systemic treatment options for advanced unresectable hepatocellular carcinoma.
Defining resectability in hepatocellular carcinoma based on burden of liver disease and Child-Pugh score.
A review of prognostic factors and the importance of understanding underlying liver disease to help stage and treat patients with hepatocellular carcinoma.
Richard S. Finn, MD, provides insight on the key risk factors that lead to hepatocellular carcinoma.
Data are reviewed from the phase 3 IMbrave150 trial for unresectable hepatocellular carcinoma.
The most interesting developments and approvals in breast cancer treatment in the last year and expectations regarding data that will be presented on at the upcoming 2020 San Antonio Breast Cancer Symposium.
